Regulation & Compliance

A new partnership with Restb.ai brings AI-powered image analysis and compliance checks directly into the NAVICA MLS, aiming to save agents time and improve data.

A new study reveals financial firms see big returns from AI but struggle with deployment due to poor data quality and IT complexity, forcing a major rethink.

The Center for the Future of Arizona launches a free, data-driven hub to equip journalists and combat declining public trust in media.

In a landmark deal for Canadian fintech, a federally regulated bank will custody QCAD's reserves, paving the way for institutional stablecoin adoption.

Thousands, including minors, were secretly filmed in Northwell Health bathrooms. A new lawsuit exposes the breach and a year-long notification delay.

A powerful new genomic tool is turning genetic doubt into diagnostic certainty, helping thousands of patients understand their true hereditary cancer risk.

With key data on its Duchenne muscular dystrophy drugs expected in 2026, Entrada's CEO Dipal Doshi will detail the firm's high-risk, high-reward strategy.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

Celcuity prepares for a key fireside chat at Guggenheim's 2026 summit, with investors eyeing crucial updates on its lead cancer drug, gedatolisib.

As Crown Crafts preps its Q3 earnings, investors watch to see if strategic shifts can overcome financial pressures in the competitive juvenile products market.

Markets are calm, but concerns over US Federal Reserve independence add a new layer of risk to global trade, threatening borrowing costs and stability.

As OneMain CEO Doug Shulman prepares for a key conference, all eyes are on the lender's strategy for navigating a complex economic and regulatory landscape.

As the FDA embraces advanced Bayesian statistics, MedTech firm BioStem sees validation for its wound care research, promising faster innovation for patients.

With AI interactions surging over 200%, 8x8's latest results show businesses are moving past AI pilots to full-scale platform adoption for CX.

Securus Technologies is launching a new AI-driven surveillance system to fix prison safety, but its controversial past casts a long shadow over its promises.

Following promising early results, RESTEM's Restem-L cell therapy enters a pivotal Phase 2/3 trial, aiming to transform treatment for IIM patients.

A new analysis of malpractice claims reveals the top drivers of patient harm in cardiology, offering critical insights to save lives and protect careers.

Humana is rolling out 'Agent Assist,' an AI tool for 20,000 advocates, aiming to enhance empathy and efficiency, not replace its human workforce.

A retired anesthesiologist suffers a catastrophic brain injury during surgery. Now, her family is taking a major healthcare provider to trial for negligence.

Genspark's 'Call for Me' AI automates tasks via phone calls, but this new convenience raises complex questions about efficiency, ethics, and the future of work.